No abstract available.
Cyclophosphamide* ; Humans* ; Stomach Neoplasms*

No abstract available.
Emphysema* ; Gallbladder*

No abstract available.

No abstract available.
Aged* ; Gallstones* ; Humans

No abstract available.

No abstract available.

BACKGROUND: Cold blood cardioplegic solution has been used to protect myocardium during open heart surgery with the hypothesis stating that it provides more oxygen supply to myocardium compared to crystalloid caridoplegic solution. We repeatedly infused cold blood cardioplegic solution to achieve myocardial protection. We biopsied a small portion of papillary muscle of patients with mitral valve replacement or double valve replacement during aortic cross-clamp time and evaluated the method of myocardial protection through the observation of changes in ultrastructure. We then analysed the relationship between changes in ultrasructure and peak postoperative CK-MB value and SGOT value. MATERIAL AND METHOD: We report observation on changes of myocardial ultrastructure, postoperative CK-MB and SGOT, and electrocardiogram in 31 patients who underwent cardiac operation. There were 11 males and 20 females, and they ranging in age from 28 to 69 years (mean score was 2.08+/-0.560, it was 2.37+/-0.558 at 40 minutes, and it was 2.36+/-0.523 at 70minutes. Mitochondrial score increased significant at 40 minutes. Mean value of postoperative peak CK-MB and SGOT were 37.3+/-17.061IU, 144.5+/-125.5IU respectively. We were not able to find any new Q were in EKG after the operation. There was no significant relationship between myocardium mitochondrial score and mean value of postoperative peak CK-MB and SGOT. CONCLUSION: In conclusion, with this study the cold blood cardioplegic solution was incomplete in preserving ultrastructure of myocardium even with satisfactory results in serum enzyme and EKG evaluation.
Aspartate Aminotransferases ; Cardioplegic Solutions ; Electrocardiography ; Female ; Heart* ; Humans ; Male ; Mitral Valve ; Myocardium ; Oxygen ; Papillary Muscles ; Thoracic Surgery*

No abstract available.

PURPOSE: Radiofrequency ablation of the great saphenous vein has proven efficacy with an excellent side effect profile, but it has the disadvantage of a lengthy pullback procedure. A new generation catheter (ClosureFast) was recently introduced to address the aforementioned procedural speed and the "ease of use" issues with using the principles of the segmental ablation technique. This study is done to report the early results after radiofrequency ablation with high ligation and using the ClosureFast catheter. METHODS: One hundred and nineteen limbs in 85 patients with great saphenous vein incompetence were treated between November, 2007 and June, 2009 with radiofrequency ablation with high ligation, and usually with adjunctive stab-avulsion phlebectomies. The patients were examined preoperatively and at 1 to 2 months postoperatively by using duplex sonography to determine the treatment's efficacy, as well as the adverse sequalae. RESULTS: The patients had an average age of 61.3+/-10.1 years (range, 32 to 80 years), and 22 (25.9%) were women. The pretreatment vein diameter measured in the supine position ranged from 5.0 to 20.0 mm (median, 8.5 mm). The total average operation time of the radiofrequency ablation with high ligation, except when performing phlebectomies, was 18.5+/-9.5 minutes. Serious complications such as deep vein thrombosis or neural injury were not observed. Paresthesia occurred in 7 limbs (5.8%). A thermal skin injury and thrombophlebitis were presented in one limb each, respectively, at the beginning period. The occlusion rate was 98.9% in 98 limbs on the follow-up at 1 to 2 months. CONCLUSION: Radiofrequency ablation with high ligation is feasible, safe and effective. However, long-term follow-up is needed in the future.
Ablation Techniques ; Catheters ; Extremities ; Female ; Follow-Up Studies ; Humans ; Ligation ; Paresthesia ; Saphenous Vein ; Skin ; Supine Position ; Thrombophlebitis ; Varicose Veins ; Veins ; Venous Thrombosis

No abstract available.
Herniorrhaphy* ; Polyethylene Terephthalates*